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Background The syndrome of ST-elevation myocardial infarction (STEMI) confirmed by typical chest pain, evolving ST-segment elevation and 
positive cardiac enzymes in the absence of obstructive CAD has been inadequately characterized.
Methods and Results In the HORIZONS-AMI trial, among a total of 3,602 pts with ongoing chest pain and confirmed electrocardiographic 
STEMI prospectively enrolled at 123 international centres, 119 pts (3.3%) had no significant stenosis (≥50%) in the epicardial coronary arteries by 
visual estimate including 85 pts (2.3%) with angiographically normal coronary arteries and 34 pts (0.94%) with non-obstructive CAD. Patients with 
absent or minimal CAD (NO-CAD) compared to pts with obstructive CAD (O-CAD) were younger, more frequently African American, less frequently 
were smokers, less likely to have had angina before index hospitalization, and had lower body mass index and lower baseline white blood count but 
higher ejection fraction. Biomarkers were subsequently elevated in 56% of these pts. Main outcomes are presented in the Table. The rates of death 
or reinfarction tended to be less in pts with NO-CAD at 30 days and 1 year, while the rates of revascularization, MACE and net adverse clinical events 
were significantly higher in the O-CAD group at 1 year.
Conclusions In the HORIZONS-AMI trial, 3.3% of the pts admitted with STEMI had non-obstructive CAD by coronary angiogram. These pts have a 
favourable 1-year prognosis. 
Endpoints, n (%)
Patients with STEMI
P value
Normal coronary angiogram or non-
obstructive CAD
N=119
Obstructive CAD
N=3475
At 30 days
Death 1 (0.9%) 92 (2.7%) 0.23
Cardiac death 1 (0.9%) 83 (2.4%) 0.28
Reinfarction 0 (0%) 66 (1.9%) 0.13
Stroke 1 (0.9%) 25 (0.7%) 0.87
Death or reinfarction 1 (0.9%) 148 (4.3%) 0.07
Ischemic TVR 0 (0%) 80 (2.3%) 0.09
Any revascularization 0 (0%) 119 (3.5%) 0.04
MACE* 2 (1.7%) 196 (5.7%) 0.07
Protocol defined major bleeding 5 (4.2%) 246 (7.1%) 0.24
Net adverse clinical events† 7 (6.0%) 389 (11.2%) 0.08
At 1 year
Death 2 (2.3%) 145 (4.2%) 0.29
Cardiac death 1 (0.9%) 104 (3.0%) 0.21
Reinfarction 1 (1.5%) 137 (4.1%) 0.16
Stroke 1 (0.9%) 39 (1.2%) 0.89
Death or reinfarction 3 (3.9%) 266 (7.8%) 0.10
Ischemic TVR 0 (0%) 223 (6.7%) 0.02
Any revascularization 0 (0.0%) 329 (9.9%) 0.003
MACE* 3 (3.3%) 416 (12.1%) 0.01
Protocol defined major bleeding 5 (4.2%) 263 (7.7%) 0.20
Net adverse clinical events† 8 (7.5%) 592 (17.2%) 0.02
*Death, reinfarction, ischemic target vessel revascularization (TVR) or stroke † MACE or protocol defined non-CABG major bleeding.
